Clinical Trial Update: A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 trial of ATG-101 in patients with advanced or metastatic solid tumors and mature B-cell Non-Hodgkin lymphoma has been terminated. The sponsor is Anten…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mature B-cell Non-hodgkin Lymphoma
• Solid Tumor

Drugs mentioned

• ATG-101

Snippet

Sponsor: Antengene (Hangzhou) Biologics Co., Ltd. | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Status: TERMINATED